Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis

R. Zivadinov, M. G. Dwyer, S. Hussein, E. Carl, C. Kennedy, M. Andrews, D. Hojnacki, M. Heininen-Brown, L. Willis, M. Cherneva, N. Bergsland, B. Weinstock-Guttman

Research output: Contribution to journalArticle

Abstract

Objective: To determine the effects of intravenous natalizumab and intramuscular interferon beta-1a (IFNβ-1a) on the volume of white-matter (WM) lesions and normal appearing brain tissue (NABT) undergoing voxel-wise (VW) increases in magnetization transfer ratio (MTR) suggestive of remyelination in patients with relapsing multiple sclerosis. Methods: This prospective, open-label, single-blinded study enrolled patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing secondary progressive multiple sclerosis (RSPMS) as well as a group of age/sex-matched healthy controls (n=22). Patients with multiple sclerosis were assigned to receive natalizumab monotherapy (n=77; RRMS/ RSPMS) or intramuscular IFNβ-1a (n=26) as either monotherapy (RRMS) or combined with pulsed i.v. methylprednisolone, as needed (RSPMS). The primary endpoint was the two-year change in volume of NABT VWMTR, by quantifying the number of voxels that increased (suggesting remyelination) or decreased (suggesting demyelination) in their MTR value. Results: The volume of tissue undergoing increases in VWMTR was significantly larger in natalizumab compared with IFNβ-1a-treated patients (year 1: p=0.001 in NABT and p

Original languageEnglish
Pages (from-to)1125-1134
Number of pages10
JournalMultiple Sclerosis Journal
Volume18
Issue number8
DOIs
Publication statusPublished - 2012

Fingerprint

Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
Brain
Methylprednisolone
Demyelinating Diseases
Age Groups
Natalizumab
Interferon beta-1a

Keywords

  • clinical trials observational study
  • MRI
  • multiple sclerosis
  • voxel-wise MTR

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Zivadinov, R., Dwyer, M. G., Hussein, S., Carl, E., Kennedy, C., Andrews, M., ... Weinstock-Guttman, B. (2012). Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis. Multiple Sclerosis Journal, 18(8), 1125-1134. https://doi.org/10.1177/1352458511433304

Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis. / Zivadinov, R.; Dwyer, M. G.; Hussein, S.; Carl, E.; Kennedy, C.; Andrews, M.; Hojnacki, D.; Heininen-Brown, M.; Willis, L.; Cherneva, M.; Bergsland, N.; Weinstock-Guttman, B.

In: Multiple Sclerosis Journal, Vol. 18, No. 8, 2012, p. 1125-1134.

Research output: Contribution to journalArticle

Zivadinov, R, Dwyer, MG, Hussein, S, Carl, E, Kennedy, C, Andrews, M, Hojnacki, D, Heininen-Brown, M, Willis, L, Cherneva, M, Bergsland, N & Weinstock-Guttman, B 2012, 'Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis', Multiple Sclerosis Journal, vol. 18, no. 8, pp. 1125-1134. https://doi.org/10.1177/1352458511433304
Zivadinov, R. ; Dwyer, M. G. ; Hussein, S. ; Carl, E. ; Kennedy, C. ; Andrews, M. ; Hojnacki, D. ; Heininen-Brown, M. ; Willis, L. ; Cherneva, M. ; Bergsland, N. ; Weinstock-Guttman, B. / Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis. In: Multiple Sclerosis Journal. 2012 ; Vol. 18, No. 8. pp. 1125-1134.
@article{5380d85954944e5cb6330605fc29e660,
title = "Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis",
abstract = "Objective: To determine the effects of intravenous natalizumab and intramuscular interferon beta-1a (IFNβ-1a) on the volume of white-matter (WM) lesions and normal appearing brain tissue (NABT) undergoing voxel-wise (VW) increases in magnetization transfer ratio (MTR) suggestive of remyelination in patients with relapsing multiple sclerosis. Methods: This prospective, open-label, single-blinded study enrolled patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing secondary progressive multiple sclerosis (RSPMS) as well as a group of age/sex-matched healthy controls (n=22). Patients with multiple sclerosis were assigned to receive natalizumab monotherapy (n=77; RRMS/ RSPMS) or intramuscular IFNβ-1a (n=26) as either monotherapy (RRMS) or combined with pulsed i.v. methylprednisolone, as needed (RSPMS). The primary endpoint was the two-year change in volume of NABT VWMTR, by quantifying the number of voxels that increased (suggesting remyelination) or decreased (suggesting demyelination) in their MTR value. Results: The volume of tissue undergoing increases in VWMTR was significantly larger in natalizumab compared with IFNβ-1a-treated patients (year 1: p=0.001 in NABT and p",
keywords = "clinical trials observational study, MRI, multiple sclerosis, voxel-wise MTR",
author = "R. Zivadinov and Dwyer, {M. G.} and S. Hussein and E. Carl and C. Kennedy and M. Andrews and D. Hojnacki and M. Heininen-Brown and L. Willis and M. Cherneva and N. Bergsland and B. Weinstock-Guttman",
year = "2012",
doi = "10.1177/1352458511433304",
language = "English",
volume = "18",
pages = "1125--1134",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis

AU - Zivadinov, R.

AU - Dwyer, M. G.

AU - Hussein, S.

AU - Carl, E.

AU - Kennedy, C.

AU - Andrews, M.

AU - Hojnacki, D.

AU - Heininen-Brown, M.

AU - Willis, L.

AU - Cherneva, M.

AU - Bergsland, N.

AU - Weinstock-Guttman, B.

PY - 2012

Y1 - 2012

N2 - Objective: To determine the effects of intravenous natalizumab and intramuscular interferon beta-1a (IFNβ-1a) on the volume of white-matter (WM) lesions and normal appearing brain tissue (NABT) undergoing voxel-wise (VW) increases in magnetization transfer ratio (MTR) suggestive of remyelination in patients with relapsing multiple sclerosis. Methods: This prospective, open-label, single-blinded study enrolled patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing secondary progressive multiple sclerosis (RSPMS) as well as a group of age/sex-matched healthy controls (n=22). Patients with multiple sclerosis were assigned to receive natalizumab monotherapy (n=77; RRMS/ RSPMS) or intramuscular IFNβ-1a (n=26) as either monotherapy (RRMS) or combined with pulsed i.v. methylprednisolone, as needed (RSPMS). The primary endpoint was the two-year change in volume of NABT VWMTR, by quantifying the number of voxels that increased (suggesting remyelination) or decreased (suggesting demyelination) in their MTR value. Results: The volume of tissue undergoing increases in VWMTR was significantly larger in natalizumab compared with IFNβ-1a-treated patients (year 1: p=0.001 in NABT and p

AB - Objective: To determine the effects of intravenous natalizumab and intramuscular interferon beta-1a (IFNβ-1a) on the volume of white-matter (WM) lesions and normal appearing brain tissue (NABT) undergoing voxel-wise (VW) increases in magnetization transfer ratio (MTR) suggestive of remyelination in patients with relapsing multiple sclerosis. Methods: This prospective, open-label, single-blinded study enrolled patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing secondary progressive multiple sclerosis (RSPMS) as well as a group of age/sex-matched healthy controls (n=22). Patients with multiple sclerosis were assigned to receive natalizumab monotherapy (n=77; RRMS/ RSPMS) or intramuscular IFNβ-1a (n=26) as either monotherapy (RRMS) or combined with pulsed i.v. methylprednisolone, as needed (RSPMS). The primary endpoint was the two-year change in volume of NABT VWMTR, by quantifying the number of voxels that increased (suggesting remyelination) or decreased (suggesting demyelination) in their MTR value. Results: The volume of tissue undergoing increases in VWMTR was significantly larger in natalizumab compared with IFNβ-1a-treated patients (year 1: p=0.001 in NABT and p

KW - clinical trials observational study

KW - MRI

KW - multiple sclerosis

KW - voxel-wise MTR

UR - http://www.scopus.com/inward/record.url?scp=84864121213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864121213&partnerID=8YFLogxK

U2 - 10.1177/1352458511433304

DO - 10.1177/1352458511433304

M3 - Article

C2 - 22194217

AN - SCOPUS:84864121213

VL - 18

SP - 1125

EP - 1134

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 8

ER -